PLCG1 mutations in cutaneous T-cell lymphomas
2014; Elsevier BV; Volume: 123; Issue: 13 Linguagem: Inglês
10.1182/blood-2013-05-504308
ISSN1528-0020
AutoresJosé P. Vaqué, Gonzalo Gómez‐López, V. Monsálvez, Ignacio Varela, Nerea Martı́nez, Cristina Pérez, Orlando Domı́nguez, Osvaldo Graña‐Castro, José Luis Rodríguez‐Peralto, Socorro María Rodríguez‐Pinilla, Carmen González‐Vela, Miriam Rubio-Camarillo, Esperanza Martín‐Sánchez, David G. Pisano, Evangelia Papadavid, Theodora Papadaki, Luis Requena, José A. García‐Marco, Míriam Méndez, Mariano Provencio, Mercedes Hospital, Dolores Suárez‐Massa, C. Postigo, David San Segundo, Marcos López‐Hoyos, Pablo L. Ortiz‐Romero, Miguel Á. Piris, Margarita Sánchez‐Beato,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoKey Points Activating mutations in PLCG1 are a frequent finding in tumoral CTCL samples. This raises the possibility of targeted therapies against PLCG1 signaling pathway, using calcineurin inhibitors.
Referência(s)